Use of anticoagulants in elderly patients: practical recommendations

References

• GoASHylekEMPhillipsKAPrevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) StudyJAMA2001285182370237511343485
   PubMed Web of Science ®Google Scholar
• AndersonFAJrWheelerHBGoldbergRJA population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT StudyArch Intern Med199115159339382025141
   PubMedGoogle Scholar
• SteinPDHullRDKayaliFGhaliWAAlshabAKOlsonREVenous thromboembolism according to age: the impact of an aging populationArch Intern Med2004164202260226515534164
   PubMedGoogle Scholar
• Weill-EngererSMeaumeSLahlouARisk factors for deep vein thrombosis in inpatients aged 65 and older: a case-control multicenter studyJ Am Geriatr Soc20045281299130415271117
   PubMed Web of Science ®Google Scholar
• AlikhanRCohenATCombeSPrevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX studyBlood Coagul Fibrinolysis200314434134612945875
   PubMed Web of Science ®Google Scholar
• Di MinnoGTufanoAChallenges in the prevention of venous thromboembolism in the elderlyJ Thromb Haemost2004281292129815304033
   PubMed Web of Science ®Google Scholar
• BrotmanDJJafferAKPrevention of venous thromboembolism in the geriatric patientCardiol Clin2008262221234vi.18406996
   PubMed Web of Science ®Google Scholar
• GeertsWHBergqvistDPineoGFPrevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Chest20081336 Suppl381S453S18574271
   PubMed Web of Science ®Google Scholar
• KearonCKahnSRAgnelliGGoldhaberSRaskobGEComerotaAJAntithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Chest20081336 Suppl454S545S18574272
   PubMed Web of Science ®Google Scholar
• LevineMNHirshJGentMOptimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosisThromb Haemost19957426066118584992
   PubMed Web of Science ®Google Scholar
• SchulmanSRhedinASLindmarkerPA comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study GroupN Engl J Med199533225166116657760866
   PubMed Web of Science ®Google Scholar
• SchulmanSGranqvistSHolmstromMThe duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study GroupN Engl J Med199733663933989010144
   PubMed Web of Science ®Google Scholar
• LeeAYLevineMNBakerRILow-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancerN Engl J Med2003349214615312853587
   PubMed Web of Science ®Google Scholar
• HeitJASilversteinMDMohrDNPettersonTMO’FallonWMMeltonLJ3rdRisk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control studyArch Intern Med2000160680981510737280
   PubMed Web of Science ®Google Scholar
• PrandoniPLensingAWPrinsMHResidual venous thrombosis as a predictive factor of recurrent venous thromboembolismAnn Intern Med20021371295596012484710
   PubMed Web of Science ®Google Scholar
• KearonCGentMHirshJA comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolismN Engl J Med19993401290190710089183
   PubMed Web of Science ®Google Scholar
• PalaretiGCosmiBLegnaniCD-dimer testing to determine the duration of anticoagulation therapyN Engl J Med2006355171780178917065639
   PubMed Web of Science ®Google Scholar
• KearonCGinsbergJSKovacsMJComparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolismN Engl J Med2003349763163912917299
   PubMed Web of Science ®Google Scholar
• RidkerPMLong-term low-dose warfarin use is effective in the prevention of recurrent venous thromboembolism: yesJ Thromb Haemost2004271034103715219181
   PubMed Web of Science ®Google Scholar
• WolfPAAbbottRDKannelWBAtrial fibrillation: a major contributor to stroke in the elderly. The Framingham StudyArch Intern Med19871479156115643632164
   PubMedGoogle Scholar
• Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trialsArch Intern Med199415413144914578018000
   PubMed Web of Science ®Google Scholar
• FangMCGoASChangYBorowskyLPomernackiNKSingerDEComparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillationJ Am Coll Cardiol200851881081518294564
   PubMed Web of Science ®Google Scholar
• GageBFWatermanADShannonWBoechlerMRichMWRadfordMJValidation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial FibrillationJAMA2001285222864287011401607
   PubMed Web of Science ®Google Scholar
• SingerDEAlbersGWDalenJEAntithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Chest20081336 Suppl546S592S18574273
   PubMed Web of Science ®Google Scholar
• BaudetEMPuelVMcBrideJTLong-term results of valve replacement with the St. Jude Medical prosthesisJ Thorac Cardiovasc Surg199510958588707739245
   PubMed Web of Science ®Google Scholar
• SalemDNO’GaraPTMadiasCPaukerSGValvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Chest20081336 Suppl593S629S18574274
   PubMed Web of Science ®Google Scholar
• SamamaMMCohenATDarmonJYA comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study GroupN Engl J Med19993411179380010477777
   PubMed Web of Science ®Google Scholar
• KleberFXWittCVogelGKoppenhagenKSchomakerUFlosbachCWRandomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory diseaseAm Heart J2003145461462112679756
   PubMed Web of Science ®Google Scholar
• LeizoroviczACohenATTurpieAGOlssonCGVaitkusPTGoldhaberSZRandomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patientsCirculation2004110787487915289368
   PubMed Web of Science ®Google Scholar
• KucherNLeizoroviczAVaitkusPTEfficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trialArch Intern Med2005165334134515710801
   PubMed Web of Science ®Google Scholar
• CohenATDavidsonBLGallusASEfficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trialBMJ2006332753732532916439370
   PubMed Web of Science ®Google Scholar
• LassenMRBauerKAErikssonBITurpieAGPostoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparisonLancet200235993191715172012049858
   PubMed Web of Science ®Google Scholar
• ColwellCWHardwickMEThromboprophylaxis in elderly patients undergoing major orthopaedic surgeryDrugs Aging200825755155818582144
   PubMed Web of Science ®Google Scholar
• TurpieAGBauerKAErikssonBILassenMRFondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studiesArch Intern Med2002162161833184012196081
   PubMed Web of Science ®Google Scholar
• BounameauxHPernegerTFondaparinux: a new synthetic pentasaccharide for thrombosis preventionLancet200235993191710171112049854
   PubMed Web of Science ®Google Scholar
• KearonCGinsbergJSJulianJAComparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolismJAMA2006296893594216926353
   PubMed Web of Science ®Google Scholar
• van DongenCJvan den BeltAGPrinsMHLensingAWFixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolismCochrane Database Syst Rev20044CD00110015495007
   PubMedGoogle Scholar
• BullerHRDavidsonBLDecoususHFondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trialAnn Intern Med20041401186787315172900
   PubMed Web of Science ®Google Scholar
• BullerHRDavidsonBLDecoususHSubcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolismN Engl J Med2003349181695170214585937
   PubMed Web of Science ®Google Scholar
• WarkentinTEMaurerBTAsterRHHeparin-induced thrombocytopenia associated with fondaparinuxN Engl J Med20073562526532655 discussion 2653–265517582083
   PubMed Web of Science ®Google Scholar
• SaviPChongBHGreinacherAEffect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparinBlood2005105113914415388575
   PubMed Web of Science ®Google Scholar
• KuoKHKovacsMJFondaparinux: a potential new therapy for HITHematology200510427127516085538
   PubMed Web of Science ®Google Scholar
• KishimotoTKViswanathanKGangulyTContaminated heparin associated with adverse clinical events and activation of the contact systemN Engl J Med2008358232457246718434646
   PubMed Web of Science ®Google Scholar
• BijsterveldNRMoonsAHBoekholdtSMAbility of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteersCirculation2002106202550255412427650
   PubMed Web of Science ®Google Scholar
• BullerHRCohenATDavidsonBIdraparinux versus standard therapy for venous thromboembolic diseaseN Engl J Med2007357111094110417855670
   PubMed Web of Science ®Google Scholar
• MantJHobbsFDFletcherKWarfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trialLancet2007370958649350317693178
   PubMed Web of Science ®Google Scholar
• SchulmanSBeythRJKearonCLevineMNHemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Chest20081336 Suppl257S298S18574268
   PubMed Web of Science ®Google Scholar
• CampbellNRHullRDBrantRHoganDBPineoGFRaskobGEAging and heparin-related bleedingArch Intern Med199615688578608774204
   PubMed Web of Science ®Google Scholar
• HirshJBauerKADonatiMBGouldMSamamaMMWeitzJIParenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Chest20081336 Suppl141S159S18574264
   PubMed Web of Science ®Google Scholar
• FangMCGoASHylekEMAge and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation studyJ Am Geriatr Soc20065481231123616913990
   PubMed Web of Science ®Google Scholar
• PalaretiGHirshJLegnaniCOral anticoagulation treatment in the elderly: a nested, prospective, case-control studyArch Intern Med2000160447047810695687
   PubMedGoogle Scholar
• HylekEMEvans-MolinaCSheaCHenaultLEReganSMajor hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillationCirculation2007115212689269617515465
   PubMed Web of Science ®Google Scholar
• Ruiz-GimenezNSuarezCGonzalezRPredictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE RegistryThromb Haemost20081001263118612534
   PubMed Web of Science ®Google Scholar
• FangMCChangYHylekEMAdvanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillationAnn Intern Med20041411074575215545674
   PubMed Web of Science ®Google Scholar
• Man-Son-HingMLaupacisAAnticoagulant-related bleeding in older persons with atrial fibrillation: physicians’ fears often unfoundedArch Intern Med2003163131580158612860581
   PubMed Web of Science ®Google Scholar
• GageBFYanYMilliganPEClinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF)Am Heart J2006151371371916504638
   PubMed Web of Science ®Google Scholar
• ShiremanTIMahnkenJDHowardPAKresowikTFHouQEllerbeckEFDevelopment of a contemporary bleeding risk model for elderly warfarin recipientsChest200613051390139617099015
   PubMed Web of Science ®Google Scholar
• NaggeJCrowtherMHirshJIs impaired renal function a contraindication to the use of low-molecular-weight heparin?Arch Intern Med2002162222605260912456233
   PubMedGoogle Scholar
• MaheIGouin-ThibaultIDrouetLElderly medical patients treated with prophylactic dosages of enoxaparin: influence of renal function on anti-Xa activity levelDrugs Aging2007241637117233548
   PubMed Web of Science ®Google Scholar
• MismettiPLaporte-SimitsidisSNavarroCAging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin)Thromb Haemost1998796116211659657442
   PubMed Web of Science ®Google Scholar
• GageBFBirman-DeychEKerznerRRadfordMJNilasenaDSRichMWIncidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fallAm J Med2005118661261715922692
   PubMed Web of Science ®Google Scholar
• AnsellJHirshJHylekEJacobsonACrowtherMPalaretiGPharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Chest20081336 Suppl160S198S18574265
   PubMed Web of Science ®Google Scholar
• JacobsLGWarfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderlyCardiol Clin2008262157167v18406992
   PubMed Web of Science ®Google Scholar
• GarciaDReganSCrowtherMHughesRAHylekEMWarfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly populationChest200512762049205615947319
   PubMed Web of Science ®Google Scholar
• SiguretVGouinIDebrayMInitiation of warfarin therapy in elderly medical inpatients: a safe and accurate regimenAm J Med2005118213714215694897
   PubMed Web of Science ®Google Scholar
• KaganskyNKnoblerHRimonEOzerZLevySSafety of anticoagulation therapy in well-informed older patientsArch Intern Med2004164182044205015477441
   PubMed Web of Science ®Google Scholar
• EikelboomJWHirshJCombined antiplatelet and anticoagulant therapy: clinical benefits and risksJ Thromb Haemost20075Suppl 125526317635734
   PubMed Web of Science ®Google Scholar
• RubboliAHalperinJLPro: ‘Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regime in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions’Thromb Haemost2008100575275318989515
   PubMed Web of Science ®Google Scholar
• BullerHDeitchmanDPrinsMSegersAEfficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging studyJ Thromb Haemost2008681313131818541000
   PubMed Web of Science ®Google Scholar
• AgnelliGGallusAGoldhaberSZTreatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59–7939 the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59–7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) studyCirculation2007116218018717576867
   PubMed Web of Science ®Google Scholar
• BullerHRLensingAWPrinsMHA dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging StudyBlood200811262242224718621928
   PubMed Web of Science ®Google Scholar
• FiessingerJNHuismanMVDavidsonBLXimelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trialJAMA2005293668168915701909
   PubMed Web of Science ®Google Scholar
• WolztMLeviMSarichTCEffect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteersThromb Haemost20049161090109615175794
   PubMed Web of Science ®Google Scholar
• GuyattGHCookDJJaeschkeRPaukerSGSchunemannHJGrades of recommendation for antithrombotic agents: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Chest20081336 Suppl123S131S18574262
   PubMed Web of Science ®Google Scholar